|
 |
SALT LAKE CITY, January 26, 2010 — BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”)) announced today the sale of two BSD-2000 hyperthermia systems to Dalian Orientech Co. LTD (“Dalian Orientech”), the Company’s exclusive Chinese distributor. The BSD 2000 system non-invasively delivers localized therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy to certain cancerous tumors, including those located deep within the body. Clinical studies have shown that hyperthermia treatment can kills cancer cells directly as well as increase the effectiveness of other cancer therapies, including radiation therapy and chemotherapy, for the treatment of certain tumors.
With the assistance of Dalian Orientech, a privately owned company, BSD obtained Chinese regulatory (SFDA) approval for the BSD-2000 in 2005, allowing Dalian Orientech to market and sell the system to hospitals throughout China. Pursuant to an exclusive distributor agreement, the Company has now placed seventeen BSD-2000 systems with Dalian Orientech in China.
Hyperthermia has been used in China for the treatment of cancer for many years, and several thousand simple hyperthermia cancer therapy systems are in place in China. The market objective for BSD in China is to continue to expand and upgrade the existing market for clinical hyperthermia equipment to the advanced features of the BSD-2000.
About BSD Medical Corporation
BSD Medical is a leading developer of systems used to provide cancer therapies requiring precision-focused heat through RF/microwave technologies. The Company’s systems have been designed to kill cancer through heat alone, and as companion therapies to improve the combined results when used along with radiation and chemotherapy treatments. The BSD-2000 Hyperthermia System is restricted to investigational use in the US. For further information visit BSD Medical\'s website at www.bsdmedical.com.
#####
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company\'s filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.
|
|
|
